



NDA 21-963

Sanofi aventis
200 Crossing Blvd, PO Box 6890
Bridgewater, NJ 08807-0890

Attention: Lori Birkenberger, Ph.D.
Associate Director, Regulatory Development

Dear Dr. Birkenberger:

Please refer to your new drug application (NDA) dated December 15, 2005, received December 16, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Allegra (fexofenadine hydrochloride) Oral Suspension.

We acknowledge receipt of your submissions dated March 1 and 6, April 13 and 14, August 3 and 29, and September 11, 2006.

This new drug application provides for a new formulation (Oral Suspension) of Allegra (fexofenadine hydrochloride) for the treatment of seasonal allergic rhinitis (SAR) in children 2 to 11 years of age and uncomplicated skin manifestations of chronic idiopathic urticaria (CIU) in children 6 months to 11 years of age.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

The final printed labeling (FPL) must be identical to, except for including the revisions indicated, the enclosed labeling (text for the package insert) and the submitted labeling (immediate container and carton labels submitted September 11, 2006). These revisions are terms of the NDA approval. Marketing the product before making the revisions, exactly as stated, in the product's labeling may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-963.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and

effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Pulmonary and Allergy Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lori Garcia, Regulatory Project Manager, at (301) 796-1212.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary Allergy Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Badrul Chowdhury
10/16/2006 04:14:20 PM